Biotechs fight fears of ‘antibiotic apocalypse’
02 September 2019
Market failure gives little incentive to develop new drugs as antimicrobial resistance grows.
Carb-X and Repair Impact Fund to fund R&D of novel antibiotics. However, Pharma needs to take over later in the development.
Further reading: Financial Times
Author(s): Clive Cookson
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
LifeArc |
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
AMR NEWS
Every two weeks in your inbox
Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!